Key Points
- Claritev SVP Tiffani Misencik sold 8,850 shares at an average price of $40.07, generating $354,619.50 and reducing her direct ownership by 6.68% to 123,723 shares.
- Claritev recently reported quarterly EPS of $1.41, beating consensus by $5.51, on revenue of $257.48 million; analysts forecast a full-year loss of $15.08 per share.
- Analyst sentiment is generally positive, with a consensus “Moderate Buy” rating and an average price target of $42.83. Institutional investors and hedge funds own 87.15% of the stock.
Claritev (NYSE:CTEV - Get Free Report) SVP Tiffani Misencik sold 8,850 shares of the company's stock in a transaction on Friday, August 14th. The shares were sold at an average price of $40.07, for a total transaction of $354,619.50. Following the completion of the sale, the senior vice president directly owned 123,723 shares in the company, valued at approximately $4,957,580.61. The trade was a 6.68% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink.
Claritev Stock Performance
Shares of CTEV opened at $35.42 on Wednesday. The company has a market capitalization of $600.37 million, a P/E ratio of -2.08 and a beta of 0.74. Claritev has a fifty-two week low of $11.50 and a fifty-two week high of $74.07. The business's 50-day moving average is $30.15 and its two-hundred day moving average is $24.14.
Claritev (NYSE:CTEV - Get Free Report) last posted its earnings results on Friday, August 7th. The company reported $1.41 earnings per share for the quarter, beating the consensus estimate of ($4.10) by $5.51. The firm had revenue of $257.48 million for the quarter. Analysts forecast that Claritev will post -15.08 EPS for the current year.
Wall Street Analysts Forecast Growth
A number of brokerages have weighed in on CTEV. Wall Street Zen upgraded shares of Claritev from a "sell" rating to a "hold" rating in a research report on Saturday, August 8th. Citigroup restated a "buy" rating and set a $45.00 target price (up from $40.00) on shares of Claritev in a research report on Monday, August 10th. Zacks Research raised Claritev from a "strong sell" rating to a "hold" rating in a report on Thursday, August 13th. Barclays assumed coverage on Claritev in a report on Friday, April 24th. They issued an "overweight" rating and a $28.00 price target for the company. Finally, Piper Sandler reissued an "overweight" rating and issued a $73.00 price objective on shares of Claritev in a report on Wednesday, August 12th. Six equities research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has issued a Sell rating to the company's stock. According to data from MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and an average price target of $42.83.
View Our Latest Stock Report on Claritev
Institutional Investors Weigh In On Claritev
Several institutional investors have recently bought and sold shares of the company. Arini Captial Management Ltd purchased a new position in Claritev in the 4th quarter valued at $64,291,000. Public Investment Fund purchased a new stake in shares of Claritev during the second quarter worth $43,703,438,000. Vanguard Group Inc. acquired a new stake in shares of Claritev in the third quarter valued at about $27,483,000. Beach Point Capital Management LP raised its position in shares of Claritev by 77.4% in the fourth quarter. Beach Point Capital Management LP now owns 755,002 shares of the company's stock valued at $32,276,000 after buying an additional 329,424 shares during the last quarter. Finally, Nomura Holdings Inc. purchased a new position in shares of Claritev in the third quarter worth about $7,817,000. 87.15% of the stock is currently owned by institutional investors and hedge funds.
Claritev Company Profile
(
Get Free Report)
Claritev is a healthcare technology, data and insights company focused on improving affordability, transparency and quality. Led by deeply experienced associates, data scientists, and innovators, Claritev provides tech-enabled solutions and services fueled by multiple data sources from over 40 years of claims repricing. Claritev utilizes world-class technology and AI solutions to power a robust enterprise platform that delivers meaningful insights to drive affordability in healthcare, brings price transparency and optimizes networks and benefits design.
See Also
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
